At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 760 enrolled
Drug / intervention
ABT-335 and rosuvastatin calcium +2 moredrug
Likely dose
ABT-335 and rosuvastatin calcium 135 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to ABT-335 and Rosuvastatin Monotherapy in Subjects With Type IIa and IIb Dyslipidemia
In Brief
A Phase 3 clinical trial evaluating ABT-335 and rosuvastatin calcium, ABT-335, and 1 other intervention for Hypercholesterolemia and Dyslipidemia. Completed, enrolled 760 participants across 168 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of ABT-335 and rosuvastatin calcium combination therapy to monotherapy in subjects with dyslipidemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia, Dyslipidemia
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2007
First PostedApr 2007
Primary CompletionFeb 2008
TodayJul 2026
First PostedApr 20, 2007
Enrollment StartApr 1, 2007
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 19.2 years ago
Interventions
ABT-335 and rosuvastatin calciumdrug
ABT-335 135 mg in combination with rosuvastatin calcium 5 mg administered orally, once daily for 12 weeks
ABT-335drug
ABT-335 135 mg monotherapy administered orally, once daily for 12 weeks
rosuvastatin calciumdrug
Rosuvastatin calcium 5 mg monotherapy administered orally, once daily for 12 weeks